Pretreatment hematocrit is negatively associated with response to neoadjuvant chemotherapy in breast cancer.
To explore the correlation between hematocrit (Hct) and response to neoadjuvant chemotherapy in breast cancer. The baseline clinicopathologic variables of included patients were retrospectively reviewed. Binary logistic regression analysis was performed to assess the predictive value of Hct on objective response. Patients in Hct <0.396 group showed higher objective response rate (ORR) compared with patients in Hct ≥0.396 group (55.8 vs 39.3%; p = 0.049), especially in human epidermal growth factor receptor 2 (HER2) overexpression subtype (p = 0.045), premenopausal patients (p = 0.019) and HER2-positve patients (p = 0.021), respectively. And Hct (OR: 0.43; 95% CI: 0.20-0.90; p = 0.024) was independently associated with ORR in breast cancer patients. Hct was negatively associated with ORR, and may serve as an independent predictive factor for ORR in breast cancer patients underwent neoadjuvant chemotherapy.